- Home
- RNA vs CHPT Comparison
RNA vs CHPT Comparison
Compare RNA & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | CHPT |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.5M | 190.2M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RNA | CHPT |
|---|---|---|
| Price | $11.54 | $7.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 9 |
| Target Price | ★ $69.26 | $9.25 |
| AVG Volume (30 Days) | 162.8K | ★ 632.2K |
| Earning Date | 01-01-0001 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $411,224,000.00 |
| Revenue This Year | $88.12 | $4.18 |
| Revenue Next Year | $18.11 | $16.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.77 | $0.58 |
| 52 Week High | $73.06 | $12.62 |
Technical Indicators
Market Signals| Indicator | RNA | CHPT |
|---|---|---|
| Relative Strength Index (RSI) | 28.33 | 51.94 |
| Support Level | N/A | $5.76 |
| Resistance Level | $14.05 | $11.01 |
| Average True Range (ATR) | 0.50 | 0.63 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.38 | 52.06 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.